IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

SR One Capital Management, LP

Q1 2025 Holdings

Filed 2025-05-13 | 12 holdings | $389.3M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Arcellx, Inc.(ACLX)Common Stock03940C100$153.9M2,346,63039.5%
ARS Pharmaceuticals, Inc.(SPRY)Common Stock82835W108$50.5M4,012,90313.0%
Mineralys Therapeutics Inc.(MLYS)Common Stock603170101$49.7M3,127,93312.8%
Zenas BioPharma, Inc(ZBIO)Common Stock98937L105$38.8M4,911,53910.0%
Crispr Therapeutics AG(CRSP)Common SharesH17182108$35.7M1,048,9519.2%
Design Therapeutics, Inc.(DSGN)Common Stock25056L103$25.2M6,526,4766.5%
Alumis Inc.(ALMS)Common Stock022307102$12.0M1,959,8963.1%
Oculis Holding AG(OCS)Ordinary SharesH5870P102$6.1M322,5001.6%
Nkarta, Inc.(NKTX)Common Stock65487U108$6.1M3,333,3331.6%
Oruka Therapeutics, Inc(ORKA)Common Stock687604108$4.4M430,3301.1%
Kala Bio, Inc.(KALA)Common Stock483119202$3.4M598,9400.9%
enGene Holdings Inc.(ENGN)Common Shares29286M105$3.3M747,7500.9%